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Human immunodeﬁciency virus (HIV)-speciﬁc cytotoxic T lymphocytes (CTL) play a major role in control
of viral replication. To understand the contribution of this antiviral response, an initial step is to fully deﬁne
the speciﬁc epitopes targeted by CTL. These studies focused on CTL responses restricted by HLA-Ap3002, one
of the HLA-A molecules most prominent in African populations. To avoid the time-consuming effort and
expense involved in culturing CTL prior to deﬁning epitopes and restricting alleles, we developed a method
combining Elispot assays with intracellular gamma interferon staining of peripheral blood mononuclear cells
to ﬁrst map the optimal epitopes targeted and then deﬁne the HLA restriction of novel epitopes. In two
Ap3002-positive subjects whose CTL responses were characterized in detail, the strongest response in both
cases was to an epitope in p17 Gag, RSLYNTVATLY (residues 76 to 86). Using this method, CTL epitopes for
which there were no motif predictions were optimized and the HLA restriction was established within 48 to 72 h
of receipt of blood. This simple and convenient approach should prove useful especially in the characterization
of CTL responses speciﬁc to HIV and other viruses, particularly in localities where performing cytotoxicity
assays would be problematic.
Human immunodeﬁciency virus (HIV)-speciﬁc cytotoxic
T lymphocytes (CTL) play a major role in controlling virus
replication (1, 8, 9, 16, 21, 24). Development of vaccines
designed to generate protective anti-HIV immune responses
requires a fundamental knowledge of the CTL epitopes that
are targeted by infected persons in populations most se-
verely affected by the epidemic. So far, however, relatively
little is known about the HIV-speciﬁc CTL epitopes that are
presented by HLA class I molecules prevalent in sub-Sa-
haran African populations, despite the estimate that 75% of
HIV infection worldwide has occurred in this region. (UNAIDS
website [http://www.unaids.org/epidemic_update/report/Epi_re-
port.htm]). This study therefore focused on one allele prominent
in southern Africa, HLA-Ap3002 (7, 15). HLA-A30 is in several
countries the commonest HLA-A allele. For example, over
50% of Zimbabweans express HLA-A30 (14). In African Zulu,
the phenotypic frequency of A30 is 44%, split approximately
equally between Ap3001 and Ap3002 (13; M. Hammond, un-
published data). In contrast, in Caucasoids, A30 is uncommon
(phenotypic frequency, 5%). No virus-speciﬁc A30-restricted
epitopes have been optimally deﬁned to date.
Initially one subject with Ap3002 was studied in detail;
ﬁve novel Ap3002-restricted CTL epitopes were deﬁned us-
ing a recently described method exploiting the sensitivity of the
Elispot assay that allows CTL epitopes to be rapidly deﬁned
using peripheral blood mononuclear cells (PBMC), and the
results were conﬁrmed by the traditional approach via cytotox-
icity assays (2). The HLA restriction, however, could not be
deﬁned by Elispot assays using PBMC incubated with a panel
of peptide-pulsed Epstein-Barr virus (EBV)-transformed B-
lymphoblastoid cell lines (BCL) because the background level
became too high, possibly due to EBV-speciﬁc responses. The
requirement to generate CTL clones or peptide-speciﬁc lines
in order to deﬁne new epitopes is technically demanding and
costly, which limits the number of laboratories that can be
equipped to deﬁne new epitopes. To circumvent this need for
culturing cells, a method for deﬁning the HLA restriction of
CTL responses by intracellular cytokine staining (ICS) assays
was developed. Thus, using the Elispot assay for rapid epitope
optimization and the ICS assay for rapid HLA restriction,
novel CTL epitopes can now be deﬁned from PBMC within 48
to 72 h of phlebotomy. In addition, this approach enables
HIV-speciﬁc CTL responses to be characterized in laborato-
ries that are not specialized in tissue culture techniques.
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1340 GOULDER ET AL. J. VIROL.MATERIALS AND METHODS
Subjects studied. Subject 199 (HLA Ap0201/p3002 Bp4402/51 Cw2/5) is a
Caucasian whose precise date of infection is unknown but who had had docu-
mented HIV infection for more than 6 years at the time of study. He is antiret-
roviral therapy naive. His viral load and CD4 count at the time of study were
3,700 HIV type 1 (HIV-1) RNA copies/ml of plasma and 811 cells/ml, respec-
tively. Subject 6007 (HLA Ap3002/2 B53/p5801 Cw4/7) is an African-Caribbean
who had been treated with highly active antiretroviral therapy for 1 year. Viral
load at time of CTL analysis was below the level of detection (,50 copies of
plasma HIV-1 RNA/ml), and the CD4
1 T-cell count was 645 cells/ml.
HLA typing and subtyping. HLA typing and subtyping were performed by
sequence-speciﬁc primer PCR (6, 17).
Peptides. Lymphocytes were tested for recognition of a panel of 290 overlap-
ping peptides, 12 to 20 amino acids in length, spanning p17 Gag, p24 Gag, Nef,
reverse transcriptase (RT), gp120, gp41, Rev, and Tat clade B SF2 sequence (35
Gag peptides provided by the NIBSC Centralized Facility for AIDS Reagents,
supported by EU Program EVA and the United Kingdom Medical Research
Council; the remainder synthesized either commercially [Research Genetics,
Huntsville, Ala.] or at the Massachusetts General Hospital Peptide Synthesis
Core). Peptides in each case overlapped by at least 10 amino acids.
Elispot assays. Fresh (PBMC) were separated from whole blood by Ficoll-
Hypaque (Sigma, St. Louis, Mo.) density gradient centrifugation and placed in
96-well polyvinylidene plates (Millipore, Bedford, Mass.) which had been pre-
coated with (0.5 mg/ml; anti-gamma interferon (IFN-g) monoclonal antibody
(MAb) 1-DIK (Mabtech, Stockholm, Sweden). The peptides were added in a
volume of 20 ml, and then PBMC were added at between 15,000 and 80,000 cells
per well in a volume of 180 ml. The end concentration of the peptides was 10 mM.
The plates were incubated overnight at 37°C and 5% CO2 and then washed with
phosphate-buffered saline before addition of the second, biotinylated anti-IFN-g
MAb, 7-B6-1 biotin (Mabtech), at 0.5 mg/ml and incubation at room temperature
for 100 min. Following washing, streptavidin-conjugated alkaline phosphatase
(Mabtech) was added at room temperature for 40 min. Individual cytokine-
producing cells were detected as dark spots after a 20-min reaction with 5-bro-
mo-4-chloro-3-indolylphosphate and nitroblue tetrazolium using an alkaline
phosphatase-conjugate substrate (Bio-Rad, Richmond, Calif.). The number of
speciﬁc T cells was calculated by subtracting the negative control values. Back-
ground was ,40/million PBMC (2 spots/well at 50,000 PBMC/well).
FIG. 2. (A) Recognition in an Elispot assay using PBMC from donor 199 of peptides differing by one residue at the N and C termini of the
optimal epitope peptide RSLYNTVATLY (RY11). (B) Recognition in a chromium release assay of truncations of the p17 Gag peptide
ELRSLYNTVATLYCV by a peptide-speciﬁc CTL line from donor 199. Target BCL were from donor EBV-522 (HLA-Ap3002/0 Bp14/2Cw8/2).
(C) HLA-Ap3002 restriction of the RY11-speciﬁc response using the same peptide-speciﬁc CTL line as in panel A and HLA-matched targets as
shown. (D) HLA-Ap3001-positive targets do not present the RY11 peptide to Ap3002-positive effectors. Ap3002-positive BCL: EBV-522 (as in
panels A and C) (diamonds); 009-BMC (Ap0201/p3002 B14/27 Cw1/8) (squares); 016-TCH (Ap3001/2 B42/2 Cw17/2) (circles). Open symbols,
BCL pulsed with no peptide; closed symbols; targets pulsed with 10 mM peptide.
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generated as previously described (19). Brieﬂy, PBMC were incubated together
with 200 mM peptide for 1 h and then resuspended in R10 medium (RPMI 1640
[Sigma], 10% fetal calf serum [Sigma], 10 mM HEPES buffer [Sigma]) with
interleukin-7 (IL-7; R&D systems) added at 40 ng/ml. Following 1 week in
culture at 37°C and 5% CO2 the medium was replaced twice weekly with R10
medium containing recombinant IL-2 (50-U/ml; kindly provided by M. Gately,
Hoffmann-La Roche, Nutley, N.J.) instead of IL-7. Chromium release assays
were performed following 2 to 4 weeks of culture.
Intracellular IFN-g staining. ICS assays were performed as described else-
where (12, 22). Brieﬂy, 0.2 3 10
6 to 1.0 3 10
6 PBMC were incubated with 4 mM
peptide and anti-CD28 and anti-CD49d MAbs (each at 1 mg/ml; Becton Dick-
inson) at 37°C and 5% CO2 for 1 h before the addition of brefeldin A (10 mg/ml;
Sigma). Following a further 6-h incubation at 37°C and 5% CO2, the cells were
placed at 4°C overnight. PBMC were then washed and stained with surface
antibodies, anti-CD8, and anti-CD3 (Becton Dickinson) at 4°C for 20 min.
Following washing, the PBMC were ﬁxed and permeabilized (Caltag, Burlin-
game, Calif.), and anti-IFN-g MAb (Becton Dickinson) was added. Cells were
then washed and analyzed. For assays using HLA-matched or mismatched BCL,
BCL that were pulsed with 10 mM peptide for 1 h were washed thrice prior to
incubation with PBMC or effectors at 10
5 BCL and 5 3 10
5 effectors in 1 ml of
R10 medium. The anti-CD28 and anti-CD49d MAbs were then added, and the
assay was carried out exactly as described above.
Generation of precursor frequency assays. Precursor frequency assays were set
up as previously described (26), using seven dilutions of PBMC from 8,000 down
to 50 cells per well in 24 replicate wells. In brief, PBMC in 96-well plates were
cultured with irradiated allogeneic feeder PBMC at 50,000 cells/well in a ﬁnal
volume per well of 200 ml of R10 medium with antibiotics (2 mM L-glutamine, 50
U of penicillin-streptomycin/ml). The anti-CD3 MAb 12F6 was added at 10
mg/ml. On day 5 and once weekly thereafter, the medium was replaced with R10
medium containing recombinant IL-2 (50 U/ml). Wells were screened for speciﬁc
recognition of HLA-matched, peptide-pulsed,
51Cr (New England Nuclear,
North Billerica, Mass.)-labelled EBV-transformed BCL target cells after 17 days
in culture.
Bulk cultured lymphocyte assay. As previously described (20), phytohemag-
glutinin-activated lymphoblasts were washed thrice and added to autologous
PBMC in a ratio of 1:4 and incubated in R10 medium at 1.5 3 10
6/ml in 50-ml
ﬂasks (Costar). Cells were cultured in the same way as described above for the
precursor frequency assays but with medium replacement with R10 medium
containing recombinant IL-2 (50 U/ml) on day 7 and thereafter twice weekly.
Expansions into additional 50-ml ﬂasks were made as necessary to maintain cell
numbers at 1 3 10
6 to 2 3 10
6/ml. The chromium release assay was performed
on day 17.
RESULTS
Deﬁnition of a strong Ap3002-restricted response to epitope
RSLYNTVATLY in p17 Gag. The approach adopted initially to
screen for HIV-speciﬁc CTL responses is illustrated in Fig. 1,
with 290 overlapping peptides spanning eight HIV-1 proteins
used in the Elispot assay. As shown for subject 199, and as also
observed in subject 6007 (not shown), strong responses were
observed within the 15-mer peptide ELRSLYNTVATLYCV
(p17 Gag residues 74 to 88). As previously described (2), op-
FIG. 3. HLA restriction of the Ap3002-RY11 response by intracellular IFN-g staining assay using peptide-speciﬁc CTL as effectors. The BCL
targets and CTL effectors used were the same as for Fig. 2C. (A) IFN-g staining following incubation of effectors with BCL that had not been
pulsed with RY11 peptide; (B) IFN-g staining following incubation of effectors with BCL that had been pulsed with 10 mM RY11 peptide and
washed thrice. Percentage of total lymphocytes gated is indicated for each plot.
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rapidity by Elispot assays using PBMC, and the same optimal
epitope RY11 was deﬁned by this method (Fig. 2A). This was
conﬁrmed as the optimal epitope by generation of a CTL line
speciﬁc for the longer 15-mer peptide ELRSLYNTVAT
LYCV, followed by cytotoxicity assays using serial truncated
peptides (Fig. 2B). This RY11-speciﬁc response was deter-
mined as HLA-Ap3002-restricted in standard chromium re-
lease assays using the peptide-speciﬁc CTL line (Fig. 2C), and
the failure of Ap3001-positive targets to present this epitope to
Ap3002-positive effectors (Fig. 2D and data not shown) dem-
onstrated the need for accurate subtyping of A30-positive sub-
jects.
Deﬁnition of HLA restriction by ICS. Previous studies had
shown that although the optimal epitope sequence can be
determined very rapidly and conveniently via Elispot assays
using PBMC (2), this approach did not allow the HLA restric-
tion of the response to be deﬁned, since a high background of
spot-forming cells was evident in Elispot plates following in-
cubation of PBMC with HLA-matched BCL even when the
BCL were not pulsed with any peptide. To circumvent this
problem, an approach to deﬁning HLA restriction via intracel-
lular IFN-g staining assays was adopted. Incubation of the
RY11 peptide-speciﬁc effector cells with BCL matched
through various of the individual HLA-A, -B, and -C alleles
expressed by donor 199 enabled the HLA restriction of the
response to be determined unequivocally as HLA-Ap3002
(Fig. 3).
To determine whether this approach could also deﬁne the
HLA restriction of a CTL response without the labor-intensive
requirement for a peptide-speciﬁc CTL line, we repeated the
assay using PBMC and the same panel of HLA-matched and
mismatched BCL that had been employed previously. The
same result was obtained by this method, as illustrated for the
same Ap3002-restricted RY11-speciﬁc response in donor 6007
(Fig. 4A and B). A comparison of the methods of deﬁning
FIG. 4. HLA restriction of Ap3002- and B60-restricted CTL responses by intracellular IFN-g staining assay using effectors within PBMC. (A
and B) HLA-Ap3002 restriction of the RY11 response described above but using PBMC from donor 6007 (Ap3002/2 B53/p5801 Cw4/7) and
Ap3002-matched BCL from donor 009-BMC (Ap0201/p3002 B14/27 Cw1/8). HLA-mismatched BCL were from donor 027-BMC (A32/34 B51/71
Cw8/16). (C and D) Comparison of HLA restriction of a B60-restricted Nef-speciﬁc response using a CTL clone from donor KM (A3/2 B14/60
Cw3/8) in a chromium release assay (C) and using PBMC from donor KM in an intracellular IFN-g staining assay with the same BCL targets (D).
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standard chromium release assays and using PBMC from a
separate subject (described in reference 2) in intracellular
IFN-g staining assays is shown also for a B60-restricted Nef-
speciﬁc response (Fig. 4C and D). These data show that this
method of deﬁning the HLA restriction of a CTL response by
intracellular IFN-g staining assay is equivalent to the standard
method using CTL clones or peptide-speciﬁc CTL lines in
terms of achieving the same result. However, this ﬂow-based
method represents a great saving in terms of the speed at
which the result can be achieved.
Deﬁnition of four further novel HLA-Ap3002-restricted CTL
epitopes. From the initial screening Elispot assays (Fig. 1),
several other responses had been detected in PBMC from
donor 199 using the sets of overlapping peptides, particularly
in RT and gp41. None were in regions containing described
FIG. 5. Optimization of four additional novel Ap3002-restricted CTL epitopes. (A and B) Optimization of the gp41-speciﬁc epitope IVN-
RVRQGY (IY9) by chromium release assay using a peptide-speciﬁc line (A; BCL targets from donor EBV-522: Ap3002/2 B14/2 Cw8/2) and
in an Elispot assay using PBMC from donor 199 (B). (C to E) Optimization of Ap3002-restricted epitopes KYCWNLLQY (KY9-gp41; C),
KLNWASQIY (KY9-RT-35; D), and KQNPDIVIY (KY9-RT-53; E) by Elispot assay using PBMC incubated with peptide. The HLA restriction
was conﬁrmed in each case using peptide-speciﬁc CTL lines in standard chromium release assays (not shown). sfc, spleen-forming cells.
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Optimization of one of the gp41-speciﬁc responses was deter-
mined by both chromium release assays using a peptide-spe-
ciﬁc line and Elispot assays using PBMC (Fig. 5A and B);
optimization of three additional epitopes was determined by
the latter approach alone (Fig. 5C to E). In each case, the
restriction for these responses was again HLA-Ap3002 (Fig. 6
and data not shown), as determined in chromium release as-
says using peptide-speciﬁc lines.
Cytolytic function of Ap3002-restricted responses. In assays
using antigen-speciﬁc CD8
1 T cells from HIV-infected sub-
jects, we have observed a strong correlation between IFN-g
production and cytolytic function (12). However, recent data
have described HIV-speciﬁc CD8
1 T cells that can produce
antiviral cytokines but are impaired in cytolytic function (3).
We therefore compared cytolytic activities toward these newly
described Ap3002-restricted epitopes to determine whether
the hierarchy of response observed from measurements of
IFN-g production following peptide stimulation in Elispot or
intracellular cytokine assays was equivalent to the hierarchy
observed from two separate measurements of cytolytic func-
tion (Fig. 6). Comparisons of the CTL precursor frequencies in
limiting dilution assays of responses toward four of the newly
described epitopes with the Elispot assays supported other
studies showing that the Elispot assay is more sensitive (12,
25), but the hierarchy of the responses was the same in the
different assays. Similarly, the hierarchy was the same in cyto-
toxicity assays using bulk cultured lymphocytes as in Elispot
assays. These data, albeit from study of a single subject show-
ing successful control of viremia, are consistent with our pre-
vious studies (12) that show a strong correlation between levels
of IFN-g-producing cells in response to HIV epitope peptides
and cytotolytic function.
DISCUSSION
These data show that strong HIV-speciﬁc responses toward
HLA-Ap3002-restricted epitopes can be generated in infected
persons. Five novel HLA-Ap3002-restricted epitopes are de-
ﬁned, of which the strongest in two subjects described was the
epitope RSLYNTVATLY (RY11) within p17 Gag. All of the
peptides have a tyrosine at the C terminus, indicating that this
is an important anchor residue for F pocket binding in the
Ap3002 binding groove. This epitope RY11 lies in a region of
clustered epitopes that includes the dominant HLA-Ap0201-
restricted epitope SLYNTVATL (5, 11). Characterization of
A30-restricted CTL responses is important since A30 is so
prevalent, found in up to 50% of populations such as those in
southern Africa that are worst afﬂicted by the global HIV
epidemic (UNAIDS website [http://unaids.org/epidemic
_update/report/Epi_report.htm]).
The second principal result of the data described is that
HLA restriction can be deﬁned by use of PBMC incubated
with peptide-pulsed BCL as antigen-presenting cells in ICS
assays. This is a valuable advance in approach to characterizing
CTL responses, since the combination of the Elispot assay as
previously described (2) and the ICS assay described here
would enable novel responses to be deﬁned precisely within 2
to 3 days of receipt of the blood sample. This increases the
speed with which novel epitopes can be deﬁned and obviates
the need for labor-intensive culture of peptide-speciﬁc CTL
lines or CTL clones followed by chromium release assays.
These factors together restrict CTL work to specialized labo-
ratories. To make the dramatic progress that is urgently
needed for a detailed understanding of the anti-HIV responses
made by infected persons in developing countries, these assays
ideally should be carried out on-site where access to the pa-
tients is least problematic. The radical simpliﬁcations to the
process of deﬁning CTL epitopes that are described here and
recently (2) now enable the characterization of HIV-speciﬁc
CTL responses to be undertaken in laboratories worldwide.
In common with many of the HLA class I molecules that are
prevalent in areas most affected by the HIV epidemic, no
HIV-speciﬁc HLA-A30-restricted CTL epitopes had previ-
ously been described. In recent studies of infected African
Zulu and Xhosa in Durban, South Africa, and of African-
Americans in Boston, Mass., it is noteworthy that strong re-
sponses to the RY11 epitope described here and detectable
responses to the gp41- and RT-speciﬁc epitopes were observed
FIG. 6. Comparison of the hierarchy of the Ap3002-restricted re-
sponses as determined by Elispot assays with the hierarchy determined
from assays of cytolytic activity. (A) Frequencies of four of the Ap3002-
restricted epitopes as shown in Elispot assays and in precursor fre-
quency assays (PFAs). (B) Hierarchy of responses toward the same
four epitope peptides in a chromium release assay using bulk cultured
lymphocytes as effectors (E) and EBV-522 Ap3002-matched
(Ap3002/2 B14/2Cw8/2) BCL as targets (T).
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However, despite detailed characterization of ﬁve Ap3001-
positive subjects using methods similar to those described here,
no Ap3001-restricted CTL epitopes have been deﬁned to date
(reference 11 and data not shown). The reasons for the infre-
quency of HIV-speciﬁc epitopes presented by prevalent HLA
class I molecules such as HLA-A1 (5) and Ap3001 remain
unknown.
A recently undertaken comparison of the peptide binding
motifs of Ap3001 and Ap3002 reveals distinctive differences
between the peptides bound by these two subtypes (18). As
previously described for HLA-A2 subtypes (4), these binding
differences correspond to functional differences, in keeping
with the data above showing that Ap3001-positive targets
pulsed with the Ap3002-deﬁned epitopes were not recognized
by Ap3002-positive effectors. These data underline the value of
accurate HLA subtyping in order to deﬁne novel CTL re-
sponses.
A feature of the Ap3002-restricted epitopes described above
that is somewhat unusual but that is consistent with the de-
scribed motif for Ap3002 is the variability of residues that can
be accommodated in position 2 (P2), normally a primary an-
chor position. To illustrate this point, the ﬁve HLA-Ap3002
epitope peptides deﬁned above are aligned in Table 1 with the
Ap3002-binding peptides that were sequenced (18). In con-
trast, there appears to be a greater restriction in the residues
that occupy P1 than P2 for the Ap3002-binding peptides
aligned in Table 1, with seven of nine peptides having either
Arg or Lys in this position. However, pool sequencing of pep-
tides eluted from Ap3002 did not identify a preference for
positively charged residue at P1 (18). The signiﬁcance of the
variability of residues that can be accommodated at P2 is in the
approach that can successfully be adopted to deﬁning further
Ap3002-restricted CTL epitopes. The method of reverse im-
munogenetics (13), which ﬁrst predicts the sequence of pep-
tides on the basis of the the peptide-binding motif, then tests
candidate peptides ﬁtting the motif for adequacy of binding,
and ﬁnally tests the binding peptides for CTL recognition, is
feasible only if the motif is relatively restricted. As can be seen
from the ﬁrst ﬁve Ap3002-restricted epitopes described here
(Table 1), each peptide carries a different residue at P2. This
suggests that an approach based on overlapping peptides as
was used here is likely to be more successful for fully charac-
terizing Ap3002-restricted virus-speciﬁc CTL responses.
One important aspect of CTL epitope characterization that
has not been addressed in these studies is the relevance to
vaccine design of CTL epitopes that are detectable in chroni-
cally infected patients using the approach described above.
The use of overlapping peptides whose sequence is based on a
published consensus sequence is clearly limited by the fact that
this sequence may not correspond to the autologous virus-
speciﬁc responses being assayed. Previously this limitation was
believed to be minor, since it was argued that conserved
epitopes within which viral escape mutations would not occur
early in infection would represent the most effective CTL re-
sponses that should be induced by vaccines (9, 20). However,
recent data from the simian immunodeﬁciency virus macaque
model (1) make the opposing argument, that epitopes in which
escape occurs earliest may indeed represent the very responses
that should be incorporated into vaccine design. If the epitopes
that are most effective in containing virus are those that lie in
variable regions, then the entire virus in each HIV-infected
subject needs to be sequenced before initiation of CTL studies.
This would clearly represent a huge investment of time and
funding and thus would not be feasible for all patients inves-
tigated; however, studies should be undertaken in selected
patients to determine the most effective CTL responses that
should be induced by a future HIV vaccine. In the meantime,
this critical issue is perhaps most likely to be resolved by future
challenge experiments carried out in macaques previously
given vaccines to induce different CTL speciﬁcities in different
groups of animals.
In conclusion, strong HIV-speciﬁc HLA-Ap3002-restricted
CTL responses in two infected subjects are described. These
are the ﬁrst A30-restricted CTL epitopes to be fully deﬁned.
These are of importance since A30 is one of the most prevalent
TABLE 1. Comparison of ﬁve newly deﬁned Ap3002-restricted CTL epitopes with the Ap3002 peptide-binding motif and the sequences of
four eluted Ap3002-binding peptides
Sequence
Residue position
d
12 3 45 6 7 8 9
a 10 11
A*3002 motif
b
Anchors VLY Y
Preferred MF HK DEP I K
Ap3002-binding peptides
Ligands
b AY KK Q F S Q Y
RI SG V D R Y Y
RL AW E V G W K Y
RY LP P M W K Y
Epitopes
c RS LY N T V A T L Y
IV RN V R Q G Y
KY CW N L L Q Y
KQ NP D I V I Y
KL NW A S Q I Y
a C-terminal position.
b Described in reference 18.
c Described in this report.
d Anchor positions P2 and P9, as identiﬁed by pool sequencing of eluted peptides (18), are underlined.
1346 GOULDER ET AL. J. VIROL.HLA class I molecules expressed in populations such as those
in southern Africa that have been most seriously affected by
the global HIV epidemic. Alignment of the novel epitopes
described illustrates a high degree of variability in the amino
acid residues that can reside at P2 within Ap3002-binding
epitope peptides. This ﬁnding is of signiﬁcance, suggesting that
an approach to deﬁning further Ap3002-restricted epitopes
speciﬁc to HIV-1 or indeed other viruses using reverse immu-
nogenetics will be relatively unsuccessful. Finally, a rapid
method of deﬁning the HLA restriction of CTL responses
using PBMC and intracellular IFN-g staining assays is de-
scribed. This will be of substantial value in reducing the time
necessary to fully deﬁne novel CTL epitopes.
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